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Constitutive protein mRNA is utilized as an index for target protein mRNA
expression in experimental models. It is assumed that constitutive protein
mRNA expression is not altered by disease states or pharmacologic interven-
tion. We evaluated whether pressure overload, or long term angiotensin con-
verting enzyme (ACE) inhibition, would alter the expression of two constitu-
tive protein mRNA:s: cyclophilin and G3PDH. 16 wk spontaneously hyperten-
sive rats (SHR) were treated with enalapril (10 mglkg; n = 9). or placebo (n =
15). for 12 wks, compared to Wistar Kyoto normal controls (n = 18). Terminal
hemodynamics were performed following therapy, with aortic flow (mean:
MAF, mlfmin). pressure (mean: MAp, mmHg), and heart rate (HR, bpm). Sys-
temic arterial resistance (SAR, units) was derived from digitized waveforms.
Myocardial function was assessed by left ventricular end diastolic pressure
(LVEDP, mmHg), and contractility (+dp/dt). Hemodynamics were followed by
harvest of left ventricle (LV). and kidney (K) tissue, which were stored at _80'
C. Total RNA was extracted, and dot blot analysis of cyclophilin and G3PDH
mRNA was performed. Each probe mRNA was quantified by densitometry,
and expressed as a relative density ratio of cyclophilin/G3PDH (C/G). Renal
tissue ACE levels (activity units) were utilized to document ACE inhibition,
and were 2.5 ± 1.3 (normal). 1.8 ± 0.8 (placebo SHR). and 1.0 ± 0.3 (enalapril
SHR, p = 0.05, compared to placebo). Analysis of variance was performed
and mean values are as given below:
Influence of Pressure Overload and ACE
Inhibitor Therapy on Constitutive Protein mRNA
Expression In the Spontaneously Hypertensive
Rat
t P < 0.05: placebo vs enalapril
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Donor organ shortage demands limiting the selection of candidates for Htx
to patients (pts) with the worst prognosis. Current pharmacological treat-
ment strategies for HF have been shown to improve survival. The purpose
of this study was to assess the prognosis of pts with symptomatic HF con-
sidered too well for Htx and to identify predictors of an adverse outcome.
Of 645 consecutive pts referred for Htx evaluation, 116 (age 46.6 ± 10.3
years, 24% females) with symptomatic HF and an ejection fraction of ~35%
(mean, 20 ± 7%) were considered too well for the procedure and formed the
study population. During a mean follow-up of 25.0 ± 14.8 months (follow-
up 99% complete), 8 (7%) cardiac deaths (7 sudden) occurred and 9 pts
(8%) required listing for Htx. Actuarial 1- and 4-year cardiac survival was 9B
± 1% and 84 ± 7% and freedom from listing for Htx was 95 ± 2% and
84 ± 7% respectively. By multivariate regression analysis inclUding base-
line clinical, hemodynamic and exercise variables, only a history of sustained
VT/aborted SCD (VTISCD) was an independent predictor of cardiac death (p
< 0.03) and longer duration of HF symptoms predicted the need for later Htx
(p = 0.004). Actuarial survival curves for patients with vs without history of
VT/SCD and with HF symptoms for> 12 months vs ~12 months are shown
below:
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Conclusion: In the current treatment era, prognosis is favorable in carefully
selected pts considered too well for Htx despite symptomatic heart failure.
A history of VT/SCD helps in identifying a subgroup at risk for sudden car-
diac death. Close observation of pts with longer duration of HF allows timely
referral for Htx if hemodynamic deterioration occurs.
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Felodipine Versus Enalapril in Heart Failure:
Results on Peak Oxygen Consumption, Holter
Recordings Hemodynamics, Neurohormones,
and Quality of Life
Rob J. de Vries 1, Michel Ouere, Dirk J. LOk, Pieter Sijbring, Jeroen J. Bucx, Peter
H. Dunselman. Working Group on Cardiovascular Research, Breda, The Netherlands;
1 Thoraxcenter, UniverSity Hospital Groningen, The Netherlands
Felodipine (FEL) is a vasoselective dihydropyridine calcium antagonist that
has shown promising results in smaller congestive heart failure (CHF) stud-
ies. Angiotensin converting enzyme inhibitors (ACEI) are the cornerstone of
CHF therapy, but many patients can not be treated with these drugs because
of side effects or contraindications. We compared the effects of FEL. 10 mg
b.Ld" and enalapril (ENA), 10 mg b.Ld., in a double blind, parallel study in
50 patients with CHF. At baseline and after 16 weeks treatment cardiopul-
monary exercise test. neurohormone sampling, Holter recording and quality
of life questionaires were assessed.
Patients: Fifty patients with CHF, NYHA class II-III, mean age 64 ± 7 yr.,
mean LVEF of 26 ± 9%, mean peak oxygen consumption of 14.8 ± 3.5
ml/minlkg. mean norepinephrine 683 ± 470 pg/ml and mean plasma renin
activity of 0.9 ± 0.8 ng/mllhr were randomized, after a 2 week placebo pe-
riod, to FEL and ENA.
Results: Exercise duration was increased 63 sec and peak oxygen con-
sumption 0.7 mllkg/min after FEL, and 60 sec and 1.4 mllkg/min after ENA
(P = NS). Rate pressure product (RPP) at peak exercise was significantly low-
ered by Fel (p < 0.005). Plasma norepinephrine decreased after both Fel and
ENA by 46 and 150 pg/ml respectively, whereas plasma renin increased by
0.7 and 4.1 ng/ml/hr respectively (both P = NS). FEL patients significantly
better results on quality of life score. Holter recordings revealed no proar-
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Endothelln-1 Modulates Conduit Vessel
Compliance as Well as Peripheral Vascular
Tone: Implications for Endotheiin Mediated
Regulation of Blood Pressure
Philip F. Binkley, Douglas Brown, Robert J. Cody. The Ohio State University,
Columbus, OH
Thus, severe pressure overload does not alter LV and K cyclophilin and
G3PDH mRNA expression in the SHR, although age-dependent changes of
mRNA expression were not evaluated in this study. Furthermore, long term
ACE inhibition did not alter their expression in a systematic manner.
Although the endothelins have well recognized effects on peripheral vascu-
lar resistance, their capacity to modulate conduit vessel tone in vivo remains
incompletely defined. Therefore, characteristic impedance of the aorta was
derived from measurement of central aortic pressure and flow in 6 normoten-
sive rats at baseline and following bolus infusion of endothelin-l , the most
potent peripheral vasoconstrictor of the endothelin peptides. Endothelin-l
produced a typical biphasic peripheral vascular response with an initial de-
crease in systemic vascular resistance (svr) (dynes-sec/cm5) from 2.1 x 105
± 0.5 x 105 to 0.5 x 105 ± 1. x 105 followed by a significant (p = 0.05) in-
crease over baseline to 2.6 x 105 ± 0.8 x 105. A significant (p = 0.02) change
in characteristic impedance of the aorta (dynes-sec/cmS) was observed with
an increase over the baseline value of 6.6 x 103 ± 2.2 x 103 to 8.1 x 103 ±
2.9 x 103: which occurred immediately following bolus infusion and during
the nadir ,n svr, followed by a return towards the baseline value (6.6 x 103
± 2.1 x 103 during the peak increase in svr). These in vivo data indicate that
significant changes in conduit vessel tone, in addition to peripheral vascu-
lar resistance, accompany administration of endothelin-l with a significant
decrease in conduit vessel compliance, reflected by increased characteris-
tic impedance, which precedes an increase in svr. Therefore, endothelin-l
modulation of systemic blood pressure may be mediated by regulation of
conduit vessel compliance as well as peripheral vascular tone.
